Corticosteroids for Children With Febrile Urinary Tract Infections
Completed
In this study the investigators will determine whether corticosteroids given at the time of urinary tract infection help prevent permanent damage to the kidneys.
Gender:
ALL
Ages:
Between 2 months and 6 years
Trial Updated:
06/24/2019
Locations: Children's Hospital of Pittsburgh, Pittsburgh, Pennsylvania
Conditions: Acute Urinary Tract Infection, Urinary Tract Infection
Study Evaluating Chemotherapy in Combination With Inotuzumab Ozogamicin In Subjects With Non-Hodgkin's Lymphoma
Completed
This is a phase 1 trial designed to evaluate safety and tolerability of chemotherapy in combination with inotuzumab ozogamicin, an investigational product, in adults with CD22-positive non-Hodgkin's lymphoma. The trial will involve two arms. In one arm, subjects will receive chemotherapy regimen R-CVP (rituximab, cyclophosphamide, vincristine and prednisone). In the other arm, subjects will receive R-GDP (rituximab, gemcitabine, cisplatinum and dexamethasone). Subjects in both arms will also rec... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/13/2019
Locations: Fox Chase Cancer Center, Philadelphia, Pennsylvania
Conditions: Lymphoma, B-Cell
A Study Comparing the Combination of Trabectedin (YONDELIS) and DOXIL/CAELYX With DOXIL/CAELYX for the Treatment of Advanced-Relapsed Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
Completed
The purpose of this study is to assess the efficacy and safety of trabectedin+DOXIL as a third-line chemotherapy regimen (treatment) in patients with platinum-sensitive advanced-relapsed epithelial ovarian, primary peritoneal, or fallopian tube cancer who received 2 previous lines of platinum-based chemotherapy.
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
03/29/2019
Locations: Not set, Abington, Pennsylvania +1 locations
Conditions: Ovarian Neoplasms, Peritoneal Neoplasms, Fallopian Tube Neoplasms
Study Evaluating the Safety of Rovalpituzumab Tesirine for Third-Line and Later Treatment of Subjects With Relapsed or Refractory Small Cell Lung Cancer
Withdrawn
A single-arm, open-label study to assess the overall safety of rovalpituzumab tesirine in participants with relapsed or refractory delta-like protein 3 (DLL3) expressing small cell lung cancer by evaluating the frequency of high grade (\>= Grade 3) select treatment-emergent adverse events (TEAEs).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/21/2018
Locations: St. Luke's Hematology Oncology /ID# 171378, Bethlehem, Pennsylvania
Conditions: Small Cell Lung Cancer
PeriOcular and INTravitreal Corticosteroids for Uveitic Macular Edema Trial
Completed
To evaluate the relative efficacy of three commonly utilized regional corticosteroids for the regional treatment of uveitic macular edema: periocular triamcinolone acetonide; intravitreal triamcinolone acetonide; intravitreal dexamethasone implant. The primary efficacy measure will be percent change in central subfield thickness as measured by OCT at 8 weeks. Participants will continue in the study for 24 weeks in order to evaluate relative effects of the 3 treatment strategies on the duration o... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/06/2018
Locations: Scheie Eye Institute, University of Pennsylvania, Philadelphia, Pennsylvania +2 locations
Conditions: Macular Edema, Uveitis
Intravitreal Dexamethasone Implant for Persistent Macular Thickening and Edema After Vitrectomy for Epiretinal Membrane
Terminated
This study seeks to evaluate the effect of the intravitreal 0.7mg dexamethasone implant on central macular thickness and visual acuity in those patients with persistent macular edema after pars plana vitrectomy for epiretinal membrane.
Gender:
ALL
Ages:
Between 18 years and 90 years
Trial Updated:
10/01/2018
Locations: Mid Atlantic Retina, Philadelphia, Pennsylvania
Conditions: Macular Edema, Epiretinal Membrane, Vitrectomy
Pain With Trigger Finger Injection: A Comparison of Steroid Alone Versus Steroid/Lidocaine Mixture
Terminated
This research is being done to compare pain relief and efficacy of trigger finger injection using a combination of lidocaine/corticosteroid versus corticosteroid injection alone versus corticosteroid/saline combination.
Gender:
ALL
Ages:
Between 18 years and 90 years
Trial Updated:
09/26/2018
Locations: Penn State Milton S. Hershey Medical Center, Hershey, Pennsylvania
Conditions: Trigger Finger Disorder
Phase II Combination Steroid and Anti-VEGF for Persistent DME
Completed
Although anti-vascular endothelial growth factor (VEGF) therapy is generally effective as treatment for center-involved diabetic macular edema (DME), a substantial proportion of anti-VEGF-treated eyes with DME do not achieve vision of 20/20 or complete resolution of retinal thickening. Indeed, over 50% of ranibizumab-treated eyes did not achieve a 2 or more line improvement in visual acuity from baseline at 2 years in Protocol I, a previous DRCR.net (Diabetic Retinopathy Clinical Research Networ... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
09/24/2018
Locations: University of Pennsylvania Scheie Eye Institute, Philadelphia, Pennsylvania
Conditions: Diabetic Macular Edema
Lenalidomide and Low-Dose Dexamethasone in Patients With Previously Treated Multiple Myeloma and Kidney Dysfunction
Terminated
Patients with previously treated multiple myeloma and kidney dysfunction will be treated with lenalidomide and low-dose dexamethasone. Phase I will study the side effects and best dose of lenalidomide when given together with low-dose dexamethasone therapy. After the maximum safe and tolerated dose is found in Phase I, the study will proceed to Phase II. Phase II will study how well the the treatment works in patients with previously treated (relapsed or refractory) multiple myeloma and kidney d... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
09/22/2018
Locations: University of Pennsylvania, Philadelphia, Pennsylvania +1 locations
Conditions: Multiple Myeloma, Plasma Cell Neoplasm
Study of the Glutaminase Inhibitor CB-839 in Hematological Tumors
Completed
Many tumor cells, in contrast to normal cells, have been shown to require the amino acid glutamine to produce energy for growth and survival. To exploit the dependence of tumors on glutamine, CB-839, a potent and selective inhibitor of the first enzyme in glutamine utilization, glutaminase, will be tested in this Phase 1 study in patients with advanced hematologic malignancies. This study is an open-label Phase 1 evaluation of CB-839 in subjects with hematological tumors. Patients will receive... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/16/2018
Locations: University of Pennsylvania, Abramson Cancer Center, Philadelphia, Pennsylvania
Conditions: Non-Hodgkin's Lymphoma (NHL), Multiple Myeloma, Waldenstrom's Macroglobulinemia (WM), Other B-cell NHL Subtypes, Including WM, T-cell NHL
Study of Bortezomib and Dexamethasone With or Without Elotuzumab to Treat Relapsed or Refractory Multiple Myeloma
Completed
The purpose of the study is to determine whether the addition of Elotuzumab to Bortezomib/ Dexamethasone will prolong the time before myeloma worsens \[progression free survival (PFS)\].
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/20/2018
Locations: St. Agnes Hospital, Baltimore, Pennsylvania +4 locations
Conditions: Multiple Myeloma
Effectiveness of Adventitial Dexamethasone in Peripheral Artery Disease
Completed
To assess the safety and effectiveness of adventitial deposition of the Study Drug in reducing inflammation and restenosis in patients with clinical evidence of claudication or critical limb ischemia and an angiographically significant lesion in the superficial femoral and/or popliteal arteries. Study Drug and Dose: Dexamethasone Sodium Phosphate Injection, USP, 4 mg/ml, with dilute contrast (17%) administered to the adventitia in a dose of 1.6 mg per cm of desired vessel treatment length.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/06/2018
Locations: UPMC Heart & Vascular Institute, Pittsburgh, Pennsylvania
Conditions: Peripheral Arterial Diseases